# A Study of TL-925 as a Treatment for Dry Eye Disease

> **NCT05745064** · PHASE2 · COMPLETED · sponsor: **Telios Pharma, Inc.** · enrollment: 107 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** TL-925
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05745064
- **Lead sponsor:** Telios Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-27
- **Primary completion:** 2023-07-11
- **Final completion:** 2023-07-11
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745064, "A Study of TL-925 as a Treatment for Dry Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05745064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*